I-Mab Announces Appointments of Richard Yeh as Chief Operating Officer and John Hayslip as Chief Medical Officer Apr 28, 2022 04:01PM
Ligand Pharma (LGND) Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab for First-Line Treatment of Advanced NSCLC in Combination with Chemotherapy Dec 22, 2021 08:05AM
Ligand’s Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly®) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy Dec 22, 2021 08:00AM
Primary Endpoint Met in Phase 3 Study of the Anti-PD-L1 Antibody Sugemalimab in Stage III Non-Small Cell Lung Cancer May 28, 2021 06:00AM
Ligand Pharma (LGND) Announces CStone Reported OmniAb-derived CS1001 Phase 3 Trial Met Primary Endpoint as First-Line Treatment in Stage IV NSCLC and Announces Plans to Submit NDA Aug 7, 2020 08:38AM


Aug 7, 2020 08:30AM CStone Announces That OmniAb-derived CS1001 (Anti-PD-L1) Phase 3 Trial Met the Primary Endpoint as First-Line Treatment in Stage IV Squamous and Non-squamous Non-Small Cell Lung Cancer and Announces P
Jan 6, 2020 08:00AM CStone Pharmaceuticals and Blueprint Medicines Initiate Phase 1b/2 Clinical Trial of Fisogatinib in Combination with CS1001 for Patients with Hepatocellular Carcinoma